country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-187938

Copy Link Print Information

EBL-3647

EBL-3647 is a LpxH inhibitor derived from JEDI-1444 (HY-187940) that blocks the essential manganese-dependent UDP-diacylglucosamine pyrophosphatase in lipid A biosynthesis. EBL-3647 exhibits antibacterial activity against wild-type E. coli and K. pneumoniae, and shows measurable MICs against efflux-deficient A. baumannii, P. aeruginosa, and P. mirabilis. EBL-3647 demonstrates in vivo efficacy against E. coli and K. pneumoniae in a mouse peritonitis model. EBL-3647 can be used for research on bacterial infections and peritonitis.

For research use only. We do not sell to patients.

CAS No.: 2851907-60-1
Formula: C₃₀H₃₇N₉O₅S₂
Molecular Weight:667.80

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

EBL-3647 Chemical Structure

CAS No.: 2851907-60-1

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC50	54 μM	Cytotoxicity against human HepG2 hepatoma cells assessed as viability reduction incubated 72 hrs by fluorometric microculture cytotoxicity assay. Cytotoxicity against human HepG2 hepatoma cells assessed as viability reduction incubated 72 hrs by fluorometric microculture cytotoxicity assay.	38579010

In Vitro

Anti-cancerBacterial InfectionOthers

Anti-cancer

EBL-3647 reduces HepG2 viability with an IC₅₀ of 54 µM^[3].

Bacterial Infection

EBL-3647 inhibits E. coli 25922 and K. pneumoniae 13883 with MICs of 2 μg/mL and 0.5-1 μg/mL, respectively, whereas efflux-deficient A. baumannii, P. aeruginosa, and P. mirabilis require 4-64 μg/mL^[1].
EBL-3647 (4× MIC) selects for spontaneous resistance at a frequency of 5.4 × 10^-10 in K. pneumoniae ATCC 13883 and at a frequency of < 8.5 × 10^-10 in E. coli 25922^[1].
EBL-3647 inhibits E. coli LpxH with an IC₅₀ of 2.2 nM; the reported MIC against E. coli 25922 is 2.0 μg/mL^[2].
EBL-3647 inhibits E. coli LpxH with an IC₅₀ of 2.2 nM^[3].
EBL-3647 inhibits the growth of E. coli ATCC 25922 with an MIC of 2 mg/L, and has an MIC of ≤0.125 mg/L against the ΔtolC efflux mutant; it inhibits K. pneumoniae ATCC 13883 with an MIC of 0.5 mg/L, and 0.25 mg/L in 50% human serum^[3].
EBL-3647 has an MIC₉₀ of 4 mg/L against E. coli isolates and 8 mg/L against K. pneumoniae isolates^[3].

Others

EBL-3647 has a human liver microsomal CL_int of 3.1 µL/mg/min and a mouse liver microsomal CL_int of <5 µL/mg/min^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bacterial Infection

EBL-3647 (subcutaneous injection; single administration) is effective in neutropenic mouse peritonitis models infected with E. coli and K. pneumoniae, with blood ED₅₀ values of 12.3 mg/kg and 21.0 mg/kg, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

CAS No. 2851907-60-1
Molecular Weight 667.80
Formula C₃₀H₃₇N₉O₅S₂
SMILES

N#CC1=CC(C)=NC(N2CCN(S(=O)(C3=CC=C(NC(C4=CC(CN5CC(C5)CN)=CC=C4N(S(=O)(C)=O)C)=O)C=C3)=O)CC2)=N1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Dome PA, et al. From Obscurity to Opportunity: LpxH Emerges as a Promising Antibiotic Target in the Battle against Gram-Negative Pathogens. ACS infectious diseases. 2025 Nov 14;11(11):2993-3008.

[2]. Ennis AF, et al. Design and Evaluation of Pyridinyl Sulfonyl Piperazine LpxH Inhibitors with Potent Antibiotic Activity Against Enterobacterales. JACS Au. 2024 Nov 25;4(11):4383-4393. [Content Brief]

[3]. Huseby DL, et al. Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria. Proceedings of the National Academy of Sciences of the United States of America. 2024 Apr 09;121(15):e2317274121.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

EBL-3647